Cellectar Biosciences Inc Dossier
Qualitative Analysis
Business overview
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of proprietary drugs for the treatment of cancer. The company's core technology is its proprietary Phospholipid Drug Conjugate (PDC) delivery platform, which is designed to selectively deliver diverse oncologic payloads (such as radioisotopes, small molecule cytotoxins, and biologics) directly to cancer cells and cancer stem cells while limiting exposure to healthy tissues. Its lead therapeutic candidate is iopofosine I 131 (also known as CLR 131), a first-in-class radioiodinated phospholipid ether conjugate targeting lipid rafts in the plasma membranes of cancer cells.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead phospholipid drug conjugate (PDC) asset, iopofosine I 131, through regulatory pathways including a planned Phase 3 confirmatory study and filing for accelerated approval with the FDA in the U.S., alongside a CMA filing with the EMA in Europe.
Expected impact: Establishes the company's first commercial-stage product in a rare bone marrow cancer with high unmet need.
Enrolling and dosing patients in the Phase 1b dose-finding study of CLR 125 (an iodine-125 Auger-emitting radiotherapeutic) for the treatment of relapsed/refractory Triple-Negative Breast Cancer (TNBC).
Expected impact: Provides clinical proof-of-concept for the company's broader Auger-emitting radiotherapeutic pipeline.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Engaged as the exclusive financial advisor to assist the Board of Directors in exploring a full range of strategic alternatives, including potential mergers, acquisitions, partnerships, joint ventures, or licensing arrangements to maximize stockholder value.
Terms: Terms of the advisory engagement have not been publicly disclosed.